Health Industry Watch
SEE OTHER BRANDS

Your healthcare and wellness news reporter

Health Industry Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.

Press releases published on May 7, 2025

Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

—  Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million —  Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million —  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, …

Exagen Inc. Announces Proposed Public Offering of Common Stock

Exagen Inc. Announces Proposed Public Offering of Common Stock

CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the …

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification RIDGE Natural History and Seroprevalence Study Highlights …

Emergent BioSolutions Reports First Quarter 2025 Financial Results

Emergent BioSolutions Reports First Quarter 2025 Financial Results

First Quarter 2025 Total Revenues of $222.2 million, decrease of 26% versus prior year First Quarter 2025 Net Income of $68.0 million, increase of 656% versus prior year First Quarter 2025 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an …

electroCore Announces First Quarter 2025 Financial Results

electroCore Announces First Quarter 2025 Financial Results

First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. (“NeuroMetrix”); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call …

Health Catalyst Reports First Quarter 2025 Results

Health Catalyst Reports First Quarter 2025 Results

SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended …

Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first …

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this year New non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio …

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management …

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration …

Anika to Participate in the Sidoti Virtual Investor Conference

Anika to Participate in the Sidoti Virtual Investor Conference

BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that …

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment …

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose- …

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System

WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and …

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results

REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM …

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund …

Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

Bionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to report financial results for the first quarter …

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML …

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s …

Cytokinetics to Hold Annual Meeting of Stockholders

Cytokinetics to Hold Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 14, 2025 at 10:00 AM Pacific Time at the Company’s headquarters, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service